Recent Updates
Recently added Catalysts
ARTV Positive Sentiment

Artiva Named a PM360 2023 Innovative Startup

Thursday, December 14, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Artiva has been acknowledged in the 2023 PM360 Innovations Issue for its pioneering work in developing the first allogeneic NK cell therapy aimed at treating lupus nephritis. The company focuses on creating safe and effective cell therapies for patients suffering from severe autoimmune diseases and cancers. Their innovative manufacturing process allows for the production of numerous doses from a single umbilical cord blood unit.

Market Sentiment Analysis

POSITIVE FACTORS

  • Artiva is recognized for innovation in cell therapy.
  • Advancement of allogeneic NK cell therapy for lupus nephritis.
  • Large-scale manufacturing capabilities enhance accessibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+215%
120-day peak, hindsight
Typical move
13.1%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK Cells
Phase 2 · Refractory Rheumatoid Arthritis (RA)

Full Press Release Details

Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis.
Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved, infusion-ready AlloNK cells from a single umbilical cord blood unit.
Read more about this recognition here.

Frequently Asked Questions

What recognition did Artiva receive in 2023?

Artiva was named an Innovative Startup in the 2023 PM360 Innovations Issue.

What is Artiva's focus in cell therapy?

Artiva aims to develop safe and effective cell therapies for autoimmune diseases and cancers.

What therapy is Artiva advancing for lupus nephritis?

Artiva is advancing the first allogeneic NK cell therapy for lupus nephritis.

How does Artiva manufacture its NK cells?

Artiva's process can produce thousands of doses from a single umbilical cord blood unit.

ShareAdd on Google
Tags: ARTV Viatris Investor Conferences Healthcare Artiva NK cell therapy lupus nephritis autoimmune diseases cell therapies
Last updated: Dec 14, 2023

Biotech snapshot

Cash runway
$349M liquidity · $7M/mo burn
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK CellsPhase 2
Refractory Rheumatoid Arthritis (RA) →

Catalyst track record

+215%
best trade around ARTV's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ARTV.

See every catalyst's timing & PoA →